Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I know , Paulson still owns 20 million plus shares !!!
Dead Cat bounce tomorrow :)
coming back !
Mathis said on CNBC that his pps target for VRX is still $10 !
Wells Fargo may be manipulating the stock via unwarranted negativity and shorting to attain his pps target so he looks smart.
Mathis and the Wells Fargo group doubled down on their negativity.
http://www.barrons.com/articles/valeant-pharmaceuticals-bears-will-be-bears-1502219218
Asia is a big market for VRX , the NK tensions don't help.
VRX is way under priced.
Nothing has changed just shorts are doing the work.
hoinb back to 22 tomorrow or day after !
Posted on another Board !
just buy it , you will be very happy EOY ! IMHO !
Here come the shorts !
I said $1.03 ! came in $1.05 !! 57 years of trading , yes I am that Old LOL !!
$16.80 last trade . to over analyze is to Paralyze.
Valeant hears from FDA.
Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA August 07, 2017 LAVAL, Quebec, Aug. 7, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%, an investigative intraocular pressure lowering single-agent eye drop for patients with open angle glaucoma or ocular hypertension. The CRL from the FDA only refers to a Current Good Manufacturing Practice (CGMP) inspection at Bausch + Lomb's manufacturing facility in Tampa, Fla. The FDA did not identify any efficacy or safety concerns with respect to the NDA or additional clinical trials needed for the approval of the NDA for latanoprostene bunod ophthalmic solution, 0.024%. Valeant will work closely with the FDA to determine the appropriate next steps for the NDA. About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com. Forward-looking Statements This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates", "if approved", "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law. Investor Contacts: Arthur Shannon arthur.shannon@valeant.com 514-856-3855 877-281-6642 (toll free) Media Contact: Lainie Keller lainie.keller@valeant.com 908-927-0617
airahim How many do you own ?
6000 +
Strong earnings !! Consensus $1.01 , my view $1.03 + on weak dollar overseas !
JLS Thanks for the info, I know about the Genetics being fast tracked.
I am looking to the 50 new products that are about to be launched by VRX.
That is caused by indiscriminant selling ,shorting etc. earnings will help that recover. IMO
I say $1.03 2nd QTR.
Time will tell. it always does !
Chris , Agree ! However VRX has 50 new products ready to be Launched.
Correct me if I am wrong .
Valeant is a SCREAMING BUY IMHO at $18 its 5 times earnings.
It Will !!
I am ready to buy more today or Monday. keeping a close eye on its movement.
The Mathis at Wells Fargo said there target is $10 on CNBC last night.... Fast moneys Karen and Tim and Russo or Rossi are long VRX and very positive !!!
Consensus $.91 to $.92 . VRX is in the quiet Period now before 2nd QTR Earnings release the morning of the 8th , 8am conference call.
http://ih.advfn.com/p.php?pid=nmona&article=75207379
Any Educated Guess's on VRX 2nd QTR earnings ? Anyone ?
The Best Performing Stocks in Canada/USA .. is ????
The best performing stocks in Canada and US in the last 3 months ... is ?????
answer:
VALEANT PHARMACEUTICALS INTERNATIONAL ( VRX )
From another Board !
Anyone tell you that this company cannot go back to $100.00
Anyone tell you that this company cannot go back to $100.00 are obviously lying thru their teeths or they don't want the stock price to go back up so quickly because they needed more time to accumulate at these cheap level... whatever the reason is ... you should know what to do by now
load up on VRX
this high flier Valeant outperformed all the high flying stocks in US like Amazon, Facebook, and Apple in the last 3 months... this turn around story is only the beginning for VRX
in the coming yrs.. they going to have multiple $billion drugs in their portfolio and their debt level will shrink to small manageable sizes FREEING UP tons of cash flow
this company is heading well above $100.00 in the coming yrs.. and you can take that to the bank
VRX is a winner
From another Board !
VALEANT OUTPERFORMED AMAZON, FACEBOOK, AND APPLE IN THE LAST 3 MONTHS.. and this is only the beginning.
From another board .
Shorting + stop loss settings+ Margin bailing .
I think on the 8th this will all turnaround and go to $19.
Time will tell as it always does.
Shorting going on IMHO .
Wells Fargo & Company Drops Coverage on Valeant Pharmaceuticals International, Inc. (VRX)>>>>>>>>>>>>>
Posted by Wayne Landers on Jul 31st, 2017
Valeant Pharmaceuticals International, Inc. logoWells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research report sent to investors on Sunday.
Several other brokerages also recently issued reports on VRX. BMO Capital Markets reiterated a hold rating and issued a $15.00 price target on shares of Valeant Pharmaceuticals International in a report on Thursday. Zacks Investment Research upgraded Valeant Pharmaceuticals International from a strong sell rating to a hold rating in a report on Thursday. J P Morgan Chase & Co set a $10.00 price target on Valeant Pharmaceuticals International and gave the company a hold rating in a report on Monday, July 17th. Deutsche Bank AG set a $19.00 price target on Valeant Pharmaceuticals International and gave the company a hold rating in a report on Monday, July 17th. Finally, Stifel Nicolaus reiterated a buy rating and issued a $35.00 price target on shares of Valeant Pharmaceuticals International in a report on Friday, June 30th. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $16.86. Valeant Pharmaceuticals International (NYSE VRX) traded down 2.26% on Friday, reaching $16.46. The company had a trading volume of 15,885,259 shares. The firm has a 50-day moving average of $15.93 and a 200-day moving average of $13.36. The stock’s market capitalization is $5.73 billion. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.93. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The firm had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.17 billion. During the same period in the prior year, the firm earned ($1.08) EPS. The firm’s quarterly revenue was down 11.1% compared to the same quarter last year. On average, equities research analysts expect that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.
In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 20,000 shares of the business’s stock in a transaction on Thursday, May 11th. The shares were purchased at an average price of $13.90 per share, with a total value of $278,000.00. Following the completion of the acquisition, the director now directly owns 70,572 shares of the company’s stock, valued at approximately $980,950.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.87% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Comerica Bank boosted its position in shares of Valeant Pharmaceuticals International by 15.2% in the fourth quarter. Comerica Bank now owns 20,145 shares of the specialty pharmaceutical company’s stock worth $309,000 after buying an additional 2,655 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Valeant Pharmaceuticals International by 86.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 576,634 shares of the specialty pharmaceutical company’s stock worth $8,372,000 after buying an additional 268,116 shares in the last quarter. Guggenheim Capital LLC boosted its position in shares of Valeant Pharmaceuticals International by 18.6% in the fourth quarter. Guggenheim Capital LLC now owns 17,540 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 2,752 shares in the last quarter. Gulf International Bank UK Ltd boosted its position in shares of Valeant Pharmaceuticals International by 1.1% in the first quarter. Gulf International Bank UK Ltd now owns 98,323 shares of the specialty pharmaceutical company’s stock worth $1,084,000 after buying an additional 1,100 shares in the last quarter. Finally, Capstone Asset Management Co. boosted its position in shares of Valeant Pharmaceuticals International by 13.6% in the first quarter. Capstone Asset Management Co. now owns 32,988 shares of the specialty pharmaceutical company’s stock worth $364,000 after buying an additional 3,940 shares in the last quarter. 50.53% of the stock is currently owned by hedge funds and other institutional investors.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses
I GUESS THEY HAVENT READ THE buy RATING YET .. lol